Vincent Lo Re III, MD, MSCE

Vincent Lo Re, MD, MSCE is Professor of Medicine in the Division of Infectious Diseases of the Robert Wood Johnson Medical School of Rutgers University and Director of the Rutgers Center for Pharmacoepidemiology and Treatment Science within the Rutgers Institute for Health. Dr. Lo Re leads an NIH-funded research program focused on pharmacoepidemiology research. He pioneered the use of electronic healthcare data for the study of liver diseases and was the first to develop computable phenotypes for many liver-related conditions, such as decompensated cirrhosis, hepatocellular carcinoma, cholangiocarcinoma, hepatic steatosis, severe acute liver injury, and acute liver failure, within electronic healthcare data. The application of these methods has led to the conduct of important pharmacoepidemiologic studies. Dr. Lo Re maintains an active clinical practice devoted to the care of patients with chronic viral hepatitis. He has chaired the US FDA's Drug Safety and Risk Management Advisory Committee since 2022. He has also served as Co-Chair of the AASLD/IDSA Hepatitis C Guidance Panel since 2022. He has been an active member of the International Society for Pharmacoepidemiology, serving on the Board of Directors from 2015-2018, Scientific Program Chair for the Society's 35th Annual Meeting in Philadelphia in August 2019, and President from 2021-2022.